BRPI0213393B8 - derivados de éter alquílico, ou um de seus sais, processo para produzir um derivado de éter alquílico, derivado de alquil-amida, ou um de seus sais, e, composição farmacêutica - Google Patents
derivados de éter alquílico, ou um de seus sais, processo para produzir um derivado de éter alquílico, derivado de alquil-amida, ou um de seus sais, e, composição farmacêuticaInfo
- Publication number
- BRPI0213393B8 BRPI0213393B8 BRPI0213393A BR0213393A BRPI0213393B8 BR PI0213393 B8 BRPI0213393 B8 BR PI0213393B8 BR PI0213393 A BRPI0213393 A BR PI0213393A BR 0213393 A BR0213393 A BR 0213393A BR PI0213393 B8 BRPI0213393 B8 BR PI0213393B8
- Authority
- BR
- Brazil
- Prior art keywords
- salts
- alkyl ether
- alkyl
- derivative
- producing
- Prior art date
Links
- 150000005215 alkyl ethers Chemical class 0.000 title abstract 5
- 150000003839 salts Chemical class 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- -1 alkyl amide Chemical class 0.000 title 1
- 210000005036 nerve Anatomy 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003302 alkenyloxy group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 abstract 1
- 125000005110 aryl thio group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 210000003050 axon Anatomy 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 230000018109 developmental process Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 208000027232 peripheral nervous system disease Diseases 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 230000008929 regeneration Effects 0.000 abstract 1
- 238000011069 regeneration method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyridine Compounds (AREA)
- Indole Compounds (AREA)
Abstract
"derivados de éter alquílico e de alquilamida ou seus sais, processo para produzir um derivado de éter alquílico, e, composição farmacêutica". os derivados de éter alquílico representados pela fórmula geral ou sais destes exibem atividades de proteger o nervo, acelerar a regeneração de nervo e potenciar o desenvolvimento de axônio e são úteis como remédios para doenças do nervo central e periférico: [1] em que r^ 1^ e r^ 2^ são cada um hidrogênio, halogênio, alquila, arila, aralquila, alcóxi, arilóxi, alquiltio, ariltio, alquenila, alquenilóxi, amino, alquilsulfonila, arilsulfonila, carbamoíla, um grupo heterocíclico, hidroxila, carboxila, nitro, oxo ou semelhantes; a é um heterociclo de cinco ou seis membros, aromático ou um anel benzênico; m e n são cada um número inteiro de 1 a 6; p é um número inteiro de 1 a 3.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001321381 | 2001-10-19 | ||
| PCT/JP2002/010827 WO2003035647A1 (fr) | 2001-10-19 | 2002-10-18 | Derives ou sels d'ether d'alkyle |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR0213393A BR0213393A (pt) | 2005-01-11 |
| BRPI0213393B1 BRPI0213393B1 (pt) | 2018-12-04 |
| BRPI0213393B8 true BRPI0213393B8 (pt) | 2021-05-25 |
Family
ID=19138603
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0213393A BRPI0213393B8 (pt) | 2001-10-19 | 2002-10-18 | derivados de éter alquílico, ou um de seus sais, processo para produzir um derivado de éter alquílico, derivado de alquil-amida, ou um de seus sais, e, composição farmacêutica |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | USRE43676E1 (pt) |
| EP (1) | EP1437353B1 (pt) |
| JP (1) | JP4398247B2 (pt) |
| KR (1) | KR100956990B1 (pt) |
| CN (2) | CN101643470B (pt) |
| AT (1) | ATE364604T1 (pt) |
| AU (1) | AU2002344107B2 (pt) |
| BR (1) | BRPI0213393B8 (pt) |
| CA (1) | CA2464358C (pt) |
| CY (1) | CY1106714T1 (pt) |
| DE (1) | DE60220694T2 (pt) |
| DK (1) | DK1437353T3 (pt) |
| ES (1) | ES2287324T3 (pt) |
| HU (1) | HU230407B1 (pt) |
| IL (2) | IL161308A0 (pt) |
| MX (1) | MXPA04003541A (pt) |
| NO (1) | NO325780B1 (pt) |
| NZ (1) | NZ532328A (pt) |
| PL (2) | PL215264B1 (pt) |
| PT (1) | PT1437353E (pt) |
| RO (1) | RO122203B1 (pt) |
| WO (1) | WO2003035647A1 (pt) |
| ZA (1) | ZA200402806B (pt) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL215264B1 (pl) * | 2001-10-19 | 2013-11-29 | Toyama Chemical Co Ltd | Pochodne eteru alkilowego lub ich sole, sposób ich wytwarzania oraz kompozycja farmaceutyczna |
| SI2389937T1 (sl) | 2002-06-14 | 2018-10-30 | Toyama Chemical Co., Ltd, | Farmacevtska sestava za izboljšanje možganske funkcije |
| KR101096528B1 (ko) * | 2003-04-17 | 2011-12-20 | 토야마 케미칼 컴퍼니 리미티드 | 알킬에테르 유도체 또는 그 염을 함유하는 망막신경질환의예방·치료제 |
| SI2348022T1 (sl) | 2005-03-28 | 2013-05-31 | Toyama Chemical Co., Ltd. | Postopek proizvodnje 1-(3-(2-(1-benzotiofen-5-il)etoksi)propil)azetidin-3-ola ali soli le-tega |
| AU2011204959B2 (en) * | 2005-03-28 | 2012-04-12 | Toyama Chemical Co., Ltd. | Process for production of 1-(3-(2-(1-benzothiophen-5-YL)- ethoxy)propyl)azetidin-3-ol or salts thereof |
| JP4902247B2 (ja) * | 2005-04-08 | 2012-03-21 | 富山化学工業株式会社 | ２−（１−ベンゾチオフェン−５−イル）エタノールの新規製造法およびその中間体 |
| JP2006328058A (ja) * | 2005-04-27 | 2006-12-07 | Toyama Chem Co Ltd | ２−（１−ベンゾチオフェン−５−イル）エタノールの新規製造法およびその中間体 |
| WO2007125913A1 (ja) * | 2006-04-26 | 2007-11-08 | Toyama Chemical Co., Ltd. | アルキルエーテル誘導体またはその塩を含有する神経細胞新生誘導剤および精神障害治療剤 |
| US8119625B2 (en) | 2006-04-26 | 2012-02-21 | Toyama Chemical Co., Ltd. | Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof |
| JP5255441B2 (ja) * | 2006-08-04 | 2013-08-07 | 富山化学工業株式会社 | アルキルエーテル誘導体またはその塩を含有するプロテインキナーゼｃ活性促進剤 |
| PT2287160E (pt) * | 2008-05-28 | 2014-06-24 | Toyama Chemical Co Ltd | Derivado de óxido de benzotiofeno e os seus sais |
| PL2818165T3 (pl) | 2012-02-22 | 2019-09-30 | Fujifilm Toyama Chemical Co., Ltd. | Stała kompozycja farmaceutyczna zawierająca 1-(3-(2-(1-benzotiofen-5-ylo)etoksy)propylo)-azetydyn-3-ol albo jego sól |
| SG10201907035TA (en) | 2014-01-31 | 2019-09-27 | Fujifilm Toyama Chemical Co Ltd | Post nerve injury rehabilitation effect-enhancing agent comprising alkyl ether derivative or salt thereof |
| US10238632B2 (en) | 2015-06-11 | 2019-03-26 | Fujifilm Toyama Chemical Co., Ltd. | Sigma receptor-binding agent |
| US11304928B2 (en) | 2015-12-25 | 2022-04-19 | Fujifilm Toyama Chemical Co., Ltd. | Tablet comprising 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or salt thereof |
| CN110121342A (zh) | 2016-12-28 | 2019-08-13 | 富士胶片富山化学株式会社 | 医药组合物 |
| US20190343796A1 (en) | 2016-12-28 | 2019-11-14 | Fujifilm Toyama Chemical Co., Ltd. | Composition for external use |
| EP3563845B1 (en) | 2016-12-28 | 2023-03-22 | FUJIFILM Toyama Chemical Co., Ltd. | Pharmaceutical composition |
| US11234962B2 (en) | 2016-12-28 | 2022-02-01 | Fujifilm Toyama Chemical Co., Ltd. | Pharmaceutical composition and method of manufacturing the same |
| BR112019024851A2 (pt) | 2017-06-02 | 2020-06-09 | Fujifilm Toyama Chemical Co Ltd | agente para evitar ou tratar atrofia cerebral |
| EP3636262A4 (en) | 2017-06-02 | 2020-06-10 | FUJIFILM Toyama Chemical Co., Ltd. | AGENT FOR PREVENTING OR TREATING ALZHEIMER-LIKE DEMENTIA |
| IL270910B2 (en) | 2017-06-02 | 2024-03-01 | Fujifilm Toyama Chemical Co Ltd | 1-(3-(2-(1-benzothiophene-5-yl)ethoxy)propyl)aztidine-3-ol or a salt thereof for use in suppressing cerebral atrophy |
| RU2019138538A (ru) | 2017-06-02 | 2021-07-09 | ФУДЖИФИЛМ Тояма Кемикал Ко., Лтд. | СРЕДСТВО ДЛЯ УМЕНЬШЕНИЯ КОЛИЧЕСТВА АМИЛОИДНОГО β-БЕЛКА |
| KR20220101001A (ko) | 2017-06-02 | 2022-07-18 | 후지필름 도야마 케미컬 가부시키가이샤 | 타우병증 예방 또는 치료제 |
| EP3705121B1 (en) * | 2017-10-30 | 2023-08-30 | FUJIFILM Toyama Chemical Co., Ltd. | Emopamil binding protein binding agent and use thereof |
| CN114853619B (zh) * | 2022-05-19 | 2024-05-10 | 神隆医药（常熟）有限公司 | 一种适于工业化生产的n-甲基酪胺盐酸盐的制备方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01156973A (ja) | 1987-09-04 | 1989-06-20 | Tanabe Seiyaku Co Ltd | ベンゾフラン誘導体 |
| JP2887492B2 (ja) | 1990-02-05 | 1999-04-26 | 富山化学工業株式会社 | １，２―エタンジオール誘導体およびその塩 |
| JP3044055B2 (ja) | 1990-08-09 | 2000-05-22 | 富山化学工業株式会社 | １，２―エタンジオール誘導体およびその塩 |
| DK74693D0 (da) | 1993-06-23 | 1993-06-23 | Novo Nordisk As | Novel heterocyclic chemistry |
| JP3232830B2 (ja) | 1993-11-30 | 2001-11-26 | 三菱電機株式会社 | フレキシブルディスク装置のキャリッジ機構 |
| PL187004B1 (pl) * | 1994-10-25 | 2004-04-30 | Toyama Chemical Co Ltd | Nowe pochodne 1,2-etanodiolu oraz kompozycje farmaceutyczne je zawierające |
| JPH08268883A (ja) | 1994-10-25 | 1996-10-15 | Toyama Chem Co Ltd | １−フェニル−１，２−エタンジオール誘導体またはそ の塩を含有する神経成長因子の作用増強剤 |
| UA59341C2 (uk) | 1995-08-11 | 2003-09-15 | Пфайзер, Інк. | (1s,2s)-1-(4-гідроксифеніл)-2-(4-гідрокси-4-фенілпіперидин-1-іл)-1-пропанолметансульфонат тригідрат |
| EP0873990A1 (en) | 1995-09-22 | 1998-10-28 | Yoshitomi Pharmaceutical Industries, Ltd. | Benzoic acid compounds and medicinal use thereof |
| DE19605610A1 (de) | 1996-02-15 | 1997-08-21 | Hoechst Ag | Substituierte Thiophenylalkenylcarbonsäureguanidide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| WO1997030703A1 (fr) | 1996-02-20 | 1997-08-28 | Toyama Chemical Co., Ltd. | Agent ameliorant les fonctions cerebrales contenant des derives de 1,2-ethanediol ou des sels de celui-ci |
| AU1506499A (en) * | 1997-12-12 | 1999-07-05 | Toyama Chemical Co. Ltd. | Alkyl ether derivatives or salts thereof and calcium antagonists containing the same |
| JP4549452B2 (ja) | 1997-12-12 | 2010-09-22 | 富山化学工業株式会社 | アルキルエーテル誘導体またはその塩並びにそれらを含有するカルシウム拮抗剤 |
| KR100641352B1 (ko) | 1999-06-11 | 2006-11-02 | 토야마 케미칼 컴퍼니 리미티드 | Ｎ-알콕시알킬-ｎ,ｎ-디알킬아민 유도체 또는 그 염, 및이를 함유하는 신경퇴행성질환 치료제 |
| PL215264B1 (pl) | 2001-10-19 | 2013-11-29 | Toyama Chemical Co Ltd | Pochodne eteru alkilowego lub ich sole, sposób ich wytwarzania oraz kompozycja farmaceutyczna |
| SI2389937T1 (sl) | 2002-06-14 | 2018-10-30 | Toyama Chemical Co., Ltd, | Farmacevtska sestava za izboljšanje možganske funkcije |
| KR101096528B1 (ko) | 2003-04-17 | 2011-12-20 | 토야마 케미칼 컴퍼니 리미티드 | 알킬에테르 유도체 또는 그 염을 함유하는 망막신경질환의예방·치료제 |
| SI2348022T1 (sl) | 2005-03-28 | 2013-05-31 | Toyama Chemical Co., Ltd. | Postopek proizvodnje 1-(3-(2-(1-benzotiofen-5-il)etoksi)propil)azetidin-3-ola ali soli le-tega |
| WO2007125913A1 (ja) | 2006-04-26 | 2007-11-08 | Toyama Chemical Co., Ltd. | アルキルエーテル誘導体またはその塩を含有する神経細胞新生誘導剤および精神障害治療剤 |
| US8119625B2 (en) | 2006-04-26 | 2012-02-21 | Toyama Chemical Co., Ltd. | Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof |
| JP5255441B2 (ja) | 2006-08-04 | 2013-08-07 | 富山化学工業株式会社 | アルキルエーテル誘導体またはその塩を含有するプロテインキナーゼｃ活性促進剤 |
| PT2287160E (pt) | 2008-05-28 | 2014-06-24 | Toyama Chemical Co Ltd | Derivado de óxido de benzotiofeno e os seus sais |
-
2002
- 2002-10-18 PL PL369601A patent/PL215264B1/pl unknown
- 2002-10-18 WO PCT/JP2002/010827 patent/WO2003035647A1/ja active IP Right Grant
- 2002-10-18 KR KR1020047005687A patent/KR100956990B1/ko active IP Right Grant
- 2002-10-18 IL IL16130802A patent/IL161308A0/xx unknown
- 2002-10-18 CA CA2464358A patent/CA2464358C/en not_active Expired - Lifetime
- 2002-10-18 BR BRPI0213393A patent/BRPI0213393B8/pt not_active IP Right Cessation
- 2002-10-18 PL PL402986A patent/PL217872B1/pl unknown
- 2002-10-18 CN CN2009102038534A patent/CN101643470B/zh not_active Expired - Lifetime
- 2002-10-18 MX MXPA04003541A patent/MXPA04003541A/es active IP Right Grant
- 2002-10-18 RO ROA200400354A patent/RO122203B1/ro unknown
- 2002-10-18 EP EP02777882A patent/EP1437353B1/en not_active Expired - Lifetime
- 2002-10-18 AT AT02777882T patent/ATE364604T1/de active
- 2002-10-18 ES ES02777882T patent/ES2287324T3/es not_active Expired - Lifetime
- 2002-10-18 HU HU0500017A patent/HU230407B1/hu unknown
- 2002-10-18 DE DE60220694T patent/DE60220694T2/de not_active Expired - Lifetime
- 2002-10-18 NZ NZ532328A patent/NZ532328A/en not_active IP Right Cessation
- 2002-10-18 US US13/327,152 patent/USRE43676E1/en not_active Expired - Lifetime
- 2002-10-18 DK DK02777882T patent/DK1437353T3/da active
- 2002-10-18 CN CNB028206452A patent/CN100500662C/zh not_active Expired - Lifetime
- 2002-10-18 AU AU2002344107A patent/AU2002344107B2/en not_active Expired
- 2002-10-18 US US10/492,774 patent/US7087594B2/en not_active Ceased
- 2002-10-18 PT PT02777882T patent/PT1437353E/pt unknown
- 2002-10-18 JP JP2003538163A patent/JP4398247B2/ja not_active Expired - Lifetime
-
2004
- 2004-04-07 IL IL161308A patent/IL161308A/en active IP Right Grant
- 2004-04-13 ZA ZA2004/02806A patent/ZA200402806B/en unknown
- 2004-04-15 NO NO20041531A patent/NO325780B1/no not_active IP Right Cessation
-
2006
- 2006-05-03 US US11/416,321 patent/US7468443B2/en not_active Expired - Lifetime
-
2007
- 2007-07-09 CY CY20071100909T patent/CY1106714T1/el unknown
-
2008
- 2008-10-17 US US12/253,379 patent/US8129535B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0213393B8 (pt) | derivados de éter alquílico, ou um de seus sais, processo para produzir um derivado de éter alquílico, derivado de alquil-amida, ou um de seus sais, e, composição farmacêutica | |
| BR0306208A (pt) | Compostos de dibenzilamina e seu uso farmacêutico | |
| BRPI0509364B8 (pt) | derivados de tetraidroquinolina, composição farmacêutica que os compreende e um processo por preparar os referidos derivados | |
| BRPI0407976A (pt) | tetrahidroisoquinolinas substituìdas em 2,5 e 2,6 para uso como moduladores de 5-ht6 | |
| BR9809697A (pt) | Composto, uso, e processo para a preparação do mesmo, composição farmacêutica, e, processo para tratar uma doença de um corpo de animal vivo, incluindo um humano | |
| BR0311541A (pt) | indol, azaindol e 4-aquenil piperidina amidas heterocìclicas relacionadas | |
| BRPI0407543A (pt) | derivados de piperidina-benzenossulfonamida | |
| BR9810592A (pt) | Composto, processos para preparar um composto, para tratar ou prevenir doenças do sistema endócrino e para a fabricação de um medicamento, composição farmacêutica, e, uso de um composto | |
| BR0315296A (pt) | Derivados do ciclohexanol espirocìclicos | |
| BRPI0509588A (pt) | derivados e tetraidronaftiridina e um processo para preparação dos mesmos | |
| BR9808281A (pt) | Compostos, composições farmacêuticas, processo para tratar doenças proliferativas e/ou distúrbios do sistema imune e para preparar um composto, e, uso de um composto | |
| BR0314393A (pt) | Piperazinas heterocìclicas substituìdas para o tratamento de esquizofrenia | |
| BR0010476A (pt) | Compostos derivados do 4,5,6,7-tetrahidroindazol e seu uso como agentes antitumorais | |
| BR0012697A (pt) | Inibidores da diferenciação de th2 | |
| BRPI0408591A (pt) | derivados de 6,7,8,9-tetrahidropirimido[1,2-a] pirimidin-4-ona 8-substituìda | |
| BR0310077A (pt) | Novos compostos e sua utilização | |
| BRPI0409110A (pt) | derivados de 4-(4-heterociclilalcoxi)fenil-1-(heterociclil-carboni l)piridina e compostos relacionados como antagonistas de histamina h3 para o tratamento de doenças neurológicas tais como alzheimer | |
| BR0215017A (pt) | Lactamas como antagonistas da taquiquinina | |
| BR0311593A (pt) | Derivados de 1-sulfonil-4-aminoalcoxi indol como moduladores de receptor 5-ht6 para tratamento dos distúrbios de snc | |
| BR0114881A (pt) | Derivados de benzoxazinona, sua preparação e uso | |
| BRPI0418255A (pt) | derivados de piperazina e piperidina n-substituìdos | |
| BR0308144A (pt) | Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto | |
| BR9814055A (pt) | Composto, composição farmacêutica, processo para o tratamento de uma doença alérgica, uso do composto, e, processos para preparar e para produzir um composto | |
| DK1194415T3 (da) | Nye piperazinylalkylthiopyrimidinderivater, farmaceutiske sammensætninger indeholdende disse samt en fremgangsmåde til deres fremstilling | |
| CO4840509A1 (es) | 2,4 diaminopirimidinas sustituidas, medicamento que contiene dichos compuestos para el control o la prevencion de enfermedades infecciosas y procedimiento para la preparacion de dichos compuestos" |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/12/2018, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B25A | Requested transfer of rights approved |
Owner name: FUJIFILM TOYAMA CHEMICAL CO., LTD. (JP) |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/10/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21A | Patent or certificate of addition expired [chapter 21.1 patent gazette] |
Free format text: PATENTE EXTINTA EM 18/10/2022 |